KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells $74,793.02 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 8,077 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now owns 94,199 shares in the company, valued at $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ KALV opened at $10.15 on Friday. The firm has a market cap of $438.63 million, a price-to-earnings ratio of -2.88 and a beta of 0.92. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.39 and a 1 year high of $16.88. The stock’s 50-day simple moving average is $11.04 and its 200-day simple moving average is $11.99.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. As a group, research analysts predict that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in KALV. Barclays PLC increased its holdings in KalVista Pharmaceuticals by 418.5% in the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after buying an additional 54,257 shares during the last quarter. Geode Capital Management LLC boosted its stake in KalVista Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company’s stock valued at $9,624,000 after purchasing an additional 24,713 shares during the period. Zimmer Partners LP raised its stake in shares of KalVista Pharmaceuticals by 52.6% in the 3rd quarter. Zimmer Partners LP now owns 95,704 shares of the specialty pharmaceutical company’s stock worth $1,108,000 after buying an additional 33,000 shares in the last quarter. Wellington Management Group LLP boosted its stake in KalVista Pharmaceuticals by 40.3% during the third quarter. Wellington Management Group LLP now owns 117,923 shares of the specialty pharmaceutical company’s stock valued at $1,366,000 after buying an additional 33,900 shares in the last quarter. Finally, State Street Corp grew its holdings in KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after acquiring an additional 515,179 shares during the period.

Analysts Set New Price Targets

KALV has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and set a $32.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).